Inotiv Discloses Initial Q4 and FY2025 Revenue Figures, Shares Surge

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Nov 18 2025

0mins

NOTV+7.18%

Should l Buy NOTV?

Source: NASDAQ.COM

Stock Performance: Inotiv, Inc. (NOTV) shares surged over 23% in overnight trading following the release of preliminary fiscal Q4 and full-year results for 2025.
Revenue Growth: The company anticipates Q4 2025 revenue between $137.5 million and $138.5 million, marking a 6% increase year-over-year, with full-year revenue expected to be slightly above $512.5 million.
Service Momentum: Inotiv reported a significant 60% year-over-year growth in its Discovery and Safety Assessment (DSA) services for Q4, alongside a book-to-bill ratio of approximately 1.08x for Q4.
Future Outlook: CEO Robert Leasure Jr. emphasized ongoing financial goals and improvements in revenue visibility, with final audited results set to be released in early December and a presentation scheduled at the Jefferies Global Healthcare Conference on November 18, 2025.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NOTV?" and start using high-conviction signals backed by rigorous historical data.

NOTV

$0.4183+Infinity%1D

Analyst Views on NOTV

Wall Street analysts forecast NOTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOTV is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.390

Low

3.00

Averages

3.00

High

3.00

Current: 0.390

Low

3.00

Averages

3.00

High

3.00

Lake Street

Frank Takkinen

Buy

downgrade

$5 -> $3

2025-12-04

Reason

Lake Street

Frank Takkinen

Price Target

$5 -> $3

AI Analysis

2025-12-04

downgrade

Buy

Reason

Lake Street analyst Frank Takkinen lowered the firm's price target on Inotiv to $3 from $5 and keeps a Buy rating on the shares. The firm, which thinks the "foundation is improving" and believes a refinancing, coupled with fewer headwinds, will allow shares to appreciate on "a realization of improved fundamentals," is lowering its target to account for its "conservatively revised estimates."

Lake Street

Frank Takkinen

Buy

downgrade

$6 -> $5

2025-05-08

Reason

Lake Street

Frank Takkinen

Price Target

$6 -> $5

2025-05-08

downgrade

Buy

Reason

Lake Street analyst Frank Takkinen lowered the firm's price target on Inotiv to $5 from $6 and keeps a Buy rating on the shares. Inotiv's recovery "continues to trend favorably," but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was "too steep," the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NOTV

Unlock Now

About NOTV

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Inotiv to Release Q1 2026 Financial Results on February 9

4 days agoNewsfilter

Earnings Release Schedule: Inotiv will issue its financial results for the first quarter of fiscal 2026 on February 9, 2026, before the stock market opens, demonstrating the company's commitment to transparency and information disclosure.
Conference Call Details: On the same day, Inotiv will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results, allowing investors to engage directly by dialing 1-800-445-7795 (Domestic) or 1-785-424-1699 (International), enhancing investor relations.
Webcast Availability: The live conference call will be accessible via the Investors section of the company's website, ensuring that those unable to attend can access an online replay, reflecting the company's dedication to investor communication.
Company Background Information: Inotiv is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, committed to increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market, highlighting its significant role in the industry.

Inotiv Partners with LifeNet Health to Enhance Drug Development Efficiency

Jan 13 2026Globenewswire

Strategic Collaboration: Inotiv announces a partnership with LifeNet Health to leverage the proprietary TruVivo® system, aiming to enhance drug development efficiency and accuracy by better aligning preclinical models with human biology.
Technological Advantage: The TruVivo® system utilizes primary human hepatocytes, providing more physiologically relevant in vitro models, thereby addressing critical challenges in drug development and potentially accelerating the development of new therapies.
Innovation Expansion: This collaboration extends beyond liver models to other human-relevant tissue models, fostering innovation for clients addressing a wide range of human diseases and enhancing market competitiveness.
Shared Vision: The partnership reflects a mutual mission to accelerate scientific innovation and improve patient safety, expected to bring more human-relevant technologies to clinical research, driving the development of safer and more effective therapies.

Inotiv Reports Q4 FY 2025 Revenue Growth of 5.9% to $138.1 Million

Dec 03 2025Newsfilter

Revenue Growth: Inotiv's Q4 FY 2025 revenue reached $138.1 million, a 5.9% increase driven primarily by a 15.7% rise in Discovery and Safety Assessment (DSA) revenue, indicating strong demand in the nonclinical drug development sector.
Reduced Operating Loss: The operating loss for Q4 decreased by 48.5% to $6.8 million, reflecting effective cost control and revenue growth strategies, suggesting an improvement in the company's financial health.
Annual Performance Improvement: Total revenue for FY 2025 was $513.0 million, up 4.5%, with Research Models and Services (RMS) revenue increasing by 4.7%, showcasing the company's stable growth potential in the market.
Adjusted EBITDA Improvement: Q4 adjusted EBITDA was $11.8 million, or 8.5% of total revenue, significantly up from $5.4 million in the prior year, indicating ongoing enhancements in profitability and operational efficiency.

Three Health Care Stocks That Could Revitalize Your Portfolio This November

Nov 18 2025Benzinga

Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.

Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading

Nov 18 2025Benzinga

Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.
Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.
Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.